Methylated DNA Marker Panels for Lung Cancer Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current lung cancer screening methods lack effective discriminant markers for accurately distinguishing between malignant and benign lung nodules, as well as different types of lung cancer, with a need for improved DNA methylation profiling to enhance detection and discrimination.
Innovation Solution
A collection of methylated methylation markers, including specific gene markers, is used to analyze tissue samples, providing high discrimination for lung cancer and distinguishing between different types, with methods such as bisulfite treatment and methylation-specific PCR to assess methylation states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA methylation profiling is used for lung cancer detection, then detection capability is improved, but discrimination between lung cancer and normal tissues remains insufficient without optimally selected markers
Solution Approach 1:
The patent segments the broad DNA methylation profiling into specific marker panels (e.g., 8-marker panel including SLC12A8, KLHDC7B, PARP15, OPLAH, BCL2L11, MAX.chr12.526, HOXB2, and EMX1) that can be independently assayed. This segmentation allows targeted detection of cancer-specific methylation patterns while ignoring irrelevant genomic regions, thereby improving discrimination accuracy between lung cancer and normal tissues.
Solution Approach 2:
The patent applies local quality by selecting markers with specific methylation characteristics that are locally optimized for lung cancer detection. The 8-marker panel was specifically chosen because these markers exhibit distinct methylation patterns in lung cancer tissues compared to normal tissues, providing high signal-to-noise ratio and enabling precise local discrimination at the marker level rather than requiring analysis of the entire genome.
2Measurement precision
If multiple markers are used in panels to improve discrimination, then detection accuracy increases, but assay complexity increases
Solution Approach 1:
The patent creates universal marker panels that can detect multiple lung cancer types (adenocarcinoma, squamous cell carcinoma, small cell carcinoma) simultaneously using the same set of markers. The 8-marker panel serves multiple functions: it detects presence of lung cancer, distinguishes cancer from normal tissue, and differentiates between cancer subtypes. This multi-functionality reduces assay complexity compared to having separate assays for each detection goal.
Solution Approach 2:
The patent merges multiple detection objectives into a single integrated assay system. The same 8-marker panel is used for both screening (distinguishing cancer from normal tissue) and classification (differentiating cancer subtypes), eliminating the need for separate assays. This merging of functions simplifies the overall diagnostic workflow while maintaining high discrimination accuracy.
Data Source
AI summary
Provided herein is technology for lung neoplasia screening and particularly, but not exclusively, to methods, compositions, and related uses for detecting the presence of lung cancer.